2011
CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
JUŘICA, Jan, Richard BARTEČEK, Ondřej ZENDULKA, Tomáš KAŠPÁREK, Eva PINDUROVÁ et. al.Základní údaje
Originální název
CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
Název česky
Stanovení fenoptypu a genotypu CYP2D6 s ohledem na predikci terapeutické odpovědi u prvních epizod schizofrenie
Název anglicky
CYP2D6 phenotype and genotype determination with respect to prediction of therapeutic response in first episode schizophrenia treatment
Autoři
JUŘICA, Jan (203 Česká republika, garant, domácí), Richard BARTEČEK (203 Česká republika, domácí), Ondřej ZENDULKA (203 Česká republika, domácí), Tomáš KAŠPÁREK (203 Česká republika, domácí), Eva PINDUROVÁ (203 Česká republika) a Alexandra ŠULCOVÁ (203 Česká republika, domácí)
Vydání
The 61th Czech-Slovak Pharmacological days and EPHAR symposium, 2011
Další údaje
Jazyk
čeština
Typ výsledku
Konferenční abstrakt
Obor
30104 Pharmacology and pharmacy
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Kód RIV
RIV/00216224:14110/11:00056990
Organizační jednotka
Lékařská fakulta
ISBN
978-80-7399-770-0
Klíčová slova česky
CYP2D6; genotyp; fenotyp; schizofrenie
Klíčová slova anglicky
CYP2D6; genotype; phenotype; schizophrenia
Změněno: 28. 11. 2011 09:07, Mgr. Michal Petr
V originále
Cytochrome P450, namely CYP2D6 is major metabolizing enzyme for many antipsychotics, including risperidone. The aim of present study was to evaluate in 35 patients with first episode of schizophrenia relation of genotype and phenotype of CYP2D6 to therapeutic response to risperidone treatment and occurrence of adverse effects. PANSS score was assessed weekly; as response was considered at least 30 % reduction of baseline of total PANSS score; CYP2D6 genotype was assessed by automatic sequencing of DNA isolated from peripheral leukocytes, phenotype was assessed using dextromethorphan as a probe substrate.
Anglicky
Cytochrome P450, namely CYP2D6 is major metabolizing enzyme for many antipsychotics, including risperidone. The aim of present study was to evaluate in 35 patients with first episode of schizophrenia relation of genotype and phenotype of CYP2D6 to therapeutic response to risperidone treatment and occurrence of adverse effects. PANSS score was assessed weekly; as response was considered at least 30 % reduction of baseline of total PANSS score; CYP2D6 genotype was assessed by automatic sequencing of DNA isolated from peripheral leukocytes, phenotype was assessed using dextromethorphan as a probe substrate.
Návaznosti
| NS9676, projekt VaV |
|